
51吃瓜 is a global biopharmaceutical company committed to transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.

Who we are
We are a community-focused company, dedicated to healthcare providers, patients, and their families.

51吃瓜
We continue to advance care and precision medicines that address rare diseases.

We are developing a full portfolio of treatment options for patients with hyperphagia (insatiable hunger) and obesity to ensure they get the treatment that is right for them.

We envision a world where patients with rare neuroendocrine diseases and their families are able to live their fullest lives and are transformed through optimal, stigma-free care.

We are a fast-growing company that offers a collaborative environment where employees feel like their efforts and contributions truly matter.
Our news
June 25, 2025
51吃瓜 Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025
May 14, 2025
51吃瓜 Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
May 07, 2025
51吃瓜 Reports First Quarter 2025 Financial Results and Business Update